Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005. (Q39805282)

14 September 2017

title

Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005. (English)

1 reference

14 September 2017

0 references

0 references

anti-retroviral agent

0 references

author name string

Andrea A Kim

1

1 reference

14 September 2017

Lucy Wanjiku

2

1 reference

14 September 2017

Doris K Macharia

3

1 reference

14 September 2017

Mary Wangai

4

1 reference

14 September 2017

Anthony Isavwa

5

1 reference

14 September 2017

Hussein Abdi

6

1 reference

14 September 2017

Barbara J Marston

7

1 reference

14 September 2017

Festus Ilako

8

1 reference

14 September 2017

Mette Kjaer

9

1 reference

14 September 2017

Kenneth Chebet

10

1 reference

14 September 2017

Kevin M De Cock

11

1 reference

14 September 2017

Paul J Weidle

12

1 reference

14 September 2017

publication date

19 July 2007

1 reference

Journal of the International Association of Providers of AIDS Care

14 September 2017

published in

1 reference

14 September 2017

volume

6

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

206-209

1 reference

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

Antiretroviral therapy in a thousand patients with AIDS in Haiti

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707304494

21 January 2018

Identifiers

DOI

10.1177/1545109707304494

1 reference

14 September 2017

1 reference